Menif S, Zarrouki S, Jeddi R, ben Alaya N, Ali Z BelHadj, Ben Abid H, Hdeiji S, Elloumi M, Khlif A, Meddeb B, Dellagi K
Laboratoire d'hématologie moléculaire et cellulaire, institut Pasteur de Tunis, Tunis, Tunisia.
Pathol Biol (Paris). 2009 Jul;57(5):388-91. doi: 10.1016/j.patbio.2007.12.010. Epub 2008 Apr 2.
The optimal management of malignant haematological disorders depend on the degree of tumor load reduction after therapy. Chronic myeloid leukemia constitutes a clinical model for molecular detection and therapy surveillance of malignant disease since this entity was the first leukemia shown to be associated with a specific bcr-abl fusion gene in the patient's leukemia cells. Molecular monitoring of bcr-abl transcript levels by real-time quantitative PCR is increasingly used to assess treatment response in patients with chronic myeloid leukemia (CML). This has become particularly relevant in the era of imatinib therapy when residual levels of leukaemia usually fall below the level of detection by bone marrow cytogenetic analysis. We monitored bcr-abl transcript levels by quantitative real time PCR in 50 tunisian patients treated with imatinib for chronic myeloid leukemia in chronic phase for a median of 29 months (3-60) after they started imatinib.
恶性血液系统疾病的最佳管理取决于治疗后肿瘤负荷降低的程度。慢性髓性白血病是恶性疾病分子检测和治疗监测的临床模型，因为该疾病是首例被证明与患者白血病细胞中特定的bcr-abl融合基因相关的白血病。通过实时定量PCR对bcr-abl转录水平进行分子监测越来越多地用于评估慢性髓性白血病（CML）患者的治疗反应。在伊马替尼治疗时代，这一点变得尤为重要，因为白血病的残留水平通常会降至骨髓细胞遗传学分析的检测水平以下。我们通过定量实时PCR监测了50例突尼斯慢性期慢性髓性白血病患者在开始伊马替尼治疗后中位29个月（3 - 60个月）的bcr-abl转录水平。
